Thrombotic events associated with low baseline direct oral anticoagulant levels in atrial fibrillation : the MAS study
© 2024 by The American Society of Hematology. Licensed under Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0), permitting only noncommercial, nonderivative use with attribution. All other rights reserved..
ABSTRACT: Although effective and safe, treatment with direct oral anticoagulants (DOAC) in atrial fibrillation (AF) is still associated with thrombotic complications. Whether the measurement of DOAC levels may improve treatment efficacy is an open issue. We carried out the observational, prospective, multicenter Measure and See (MAS) study. Blood was collected 15 to 30 days after starting DOAC treatment in patients with AF who were followed-up for 1 year. Plasma samples were centralized for DOAC level measurement. Patients' DOAC levels were converted into drug/dosage standardized values to allow a pooled analysis in a time-dependent, competitive-risk model. The measured values were transformed into standardized values (representing the distance of each value from the overall mean) by subtracting the DOAC-specific mean value from the original values and dividing by the standard deviation. Trough and peak DOAC levels were assessed in 1657 and 1303 patients, respectively. In total, 21 thrombotic complications were recorded during 1606 years of follow-up (incidence of 1.31% of patients per year). Of 21 thrombotic events, 17 occurred in patients whose standardized activity levels were below the mean of each DOAC (0); the incidence was the highest (4.82% of patients per year) in patients whose standardized values were in the lowest class (-1.00 or less). Early measurement of DOAC levels in patients with AF allowed us to identify most of the patients who, having low baseline DOAC levels, subsequently developed thrombotic complications. Further studies are warranted to assess whether thrombotic complications may be reduced by measuring baseline DOAC levels and modifying treatment when indicated. This trial was registered at www.ClinicalTrials.gov as #NCT03803579.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:8 |
|---|---|
| Enthalten in: |
Blood advances - 8(2024), 8 vom: 23. Apr., Seite 1846-1856 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Testa, Sophie [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Anticoagulants |
|---|
| Anmerkungen: |
Date Completed 11.04.2024 Date Revised 25.04.2024 published: Print ClinicalTrials.gov: NCT03803579 Citation Status MEDLINE |
|---|
| doi: |
10.1182/bloodadvances.2023012408 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM368843696 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM368843696 | ||
| 003 | DE-627 | ||
| 005 | 20240425232946.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 240229s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1182/bloodadvances.2023012408 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1386.xml |
| 035 | |a (DE-627)NLM368843696 | ||
| 035 | |a (NLM)38394387 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Testa, Sophie |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Thrombotic events associated with low baseline direct oral anticoagulant levels in atrial fibrillation |b the MAS study |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 11.04.2024 | ||
| 500 | |a Date Revised 25.04.2024 | ||
| 500 | |a published: Print | ||
| 500 | |a ClinicalTrials.gov: NCT03803579 | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a © 2024 by The American Society of Hematology. Licensed under Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0), permitting only noncommercial, nonderivative use with attribution. All other rights reserved. | ||
| 520 | |a ABSTRACT: Although effective and safe, treatment with direct oral anticoagulants (DOAC) in atrial fibrillation (AF) is still associated with thrombotic complications. Whether the measurement of DOAC levels may improve treatment efficacy is an open issue. We carried out the observational, prospective, multicenter Measure and See (MAS) study. Blood was collected 15 to 30 days after starting DOAC treatment in patients with AF who were followed-up for 1 year. Plasma samples were centralized for DOAC level measurement. Patients' DOAC levels were converted into drug/dosage standardized values to allow a pooled analysis in a time-dependent, competitive-risk model. The measured values were transformed into standardized values (representing the distance of each value from the overall mean) by subtracting the DOAC-specific mean value from the original values and dividing by the standard deviation. Trough and peak DOAC levels were assessed in 1657 and 1303 patients, respectively. In total, 21 thrombotic complications were recorded during 1606 years of follow-up (incidence of 1.31% of patients per year). Of 21 thrombotic events, 17 occurred in patients whose standardized activity levels were below the mean of each DOAC (0); the incidence was the highest (4.82% of patients per year) in patients whose standardized values were in the lowest class (-1.00 or less). Early measurement of DOAC levels in patients with AF allowed us to identify most of the patients who, having low baseline DOAC levels, subsequently developed thrombotic complications. Further studies are warranted to assess whether thrombotic complications may be reduced by measuring baseline DOAC levels and modifying treatment when indicated. This trial was registered at www.ClinicalTrials.gov as #NCT03803579 | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Multicenter Study | |
| 650 | 4 | |a Observational Study | |
| 650 | 7 | |a Anticoagulants |2 NLM | |
| 700 | 1 | |a Palareti, Gualtiero |e verfasserin |4 aut | |
| 700 | 1 | |a Legnani, Cristina |e verfasserin |4 aut | |
| 700 | 1 | |a Dellanoce, Claudia |e verfasserin |4 aut | |
| 700 | 1 | |a Cini, Michela |e verfasserin |4 aut | |
| 700 | 1 | |a Paoletti, Oriana |e verfasserin |4 aut | |
| 700 | 1 | |a Ciampa, Antonio |e verfasserin |4 aut | |
| 700 | 1 | |a Antonucci, Emilia |e verfasserin |4 aut | |
| 700 | 1 | |a Poli, Daniela |e verfasserin |4 aut | |
| 700 | 1 | |a Morandini, Rossella |e verfasserin |4 aut | |
| 700 | 1 | |a Tala, Maurizio |e verfasserin |4 aut | |
| 700 | 1 | |a Chiarugi, Paolo |e verfasserin |4 aut | |
| 700 | 1 | |a Santoro, Rita Carlotta |e verfasserin |4 aut | |
| 700 | 1 | |a Iannone, Angela Maria |e verfasserin |4 aut | |
| 700 | 1 | |a De Candia, Erica |e verfasserin |4 aut | |
| 700 | 1 | |a Pignatelli, Pasquale |e verfasserin |4 aut | |
| 700 | 1 | |a Faioni, Elena Maria |e verfasserin |4 aut | |
| 700 | 1 | |a Chistolini, Antonio |e verfasserin |4 aut | |
| 700 | 1 | |a Esteban, Maria Del Pilar |e verfasserin |4 aut | |
| 700 | 1 | |a Marietta, Marco |e verfasserin |4 aut | |
| 700 | 1 | |a Tripodi, Armando |e verfasserin |4 aut | |
| 700 | 1 | |a Tosetto, Alberto |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Blood advances |d 2016 |g 8(2024), 8 vom: 23. Apr., Seite 1846-1856 |w (DE-627)NLM268683263 |x 2473-9537 |7 nnns |
| 773 | 1 | 8 | |g volume:8 |g year:2024 |g number:8 |g day:23 |g month:04 |g pages:1846-1856 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1182/bloodadvances.2023012408 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 8 |j 2024 |e 8 |b 23 |c 04 |h 1846-1856 | ||